Gilead Sciences, Inc. (GILD) Shares Bought by Notis McConarty Edward

Notis McConarty Edward grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 16,682 shares of the biopharmaceutical company’s stock after buying an additional 2,435 shares during the period. Notis McConarty Edward’s holdings in Gilead Sciences were worth $1,133,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Stellar Capital Management LLC increased its stake in shares of Gilead Sciences by 7.6% during the first quarter. Stellar Capital Management LLC now owns 13,395 shares of the biopharmaceutical company’s stock valued at $910,000 after buying an additional 947 shares during the period. Gareth Morgan Investments Limited Partnership increased its stake in shares of Gilead Sciences by 1.5% during the first quarter. Gareth Morgan Investments Limited Partnership now owns 57,785 shares of the biopharmaceutical company’s stock valued at $3,925,000 after buying an additional 873 shares during the period. Marshall & Sullivan Inc. WA increased its stake in shares of Gilead Sciences by 11.8% during the first quarter. Marshall & Sullivan Inc. WA now owns 21,337 shares of the biopharmaceutical company’s stock valued at $1,405,000 after buying an additional 2,255 shares during the period. Lumbard & Kellner LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at approximately $516,000. Finally, Tudor Investment Corp ET AL increased its stake in shares of Gilead Sciences by 81.6% during the first quarter. Tudor Investment Corp ET AL now owns 20,709 shares of the biopharmaceutical company’s stock valued at $1,407,000 after buying an additional 9,308 shares during the period. 74.05% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by Notis McConarty Edward” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.themarketsdaily.com/2017/09/12/gilead-sciences-inc-gild-shares-bought-by-notis-mcconarty-edward.html.

Gilead Sciences, Inc. (GILD) traded down 0.44% during mid-day trading on Tuesday, reaching $84.15. The company had a trading volume of 4,753,093 shares. The firm has a market capitalization of $109.89 billion, a PE ratio of 9.14 and a beta of 1.19. The stock’s 50-day moving average price is $75.90 and its 200 day moving average price is $69.72. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the firm posted $3.08 EPS. The firm’s revenue was down 8.2% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.46%. Gilead Sciences’s dividend payout ratio is currently 22.58%.

In other news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the transaction, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the transaction, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 466,819 shares of company stock valued at $36,740,240. 1.30% of the stock is currently owned by insiders.

Several equities analysts have recently issued reports on GILD shares. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Thursday, August 31st. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 target price on the stock in a research note on Monday, June 26th. Credit Suisse Group reissued an “outperform” rating and set a $79.00 target price on shares of Gilead Sciences in a research note on Monday, May 15th. Finally, Deutsche Bank AG reissued a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. Eleven research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $83.06.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply